PURPOSE: Due to the problem of high ceiling effects of the EQ-5D-3L, the EQ-5D-5L was developed. However, little was known about the full psychometric properties of the EQ-5D-5L. Thus, this study aimed to evaluate its practicality, reliability, validity, and responsiveness in Thai patients with chronic diseases. METHODS: One thousand one hundred and fifty-six adults taking a medicine at least 3 months were identified from three university hospitals in Bangkok, Thailand, between July 2014 and March 2015. Practicality was evaluated by administration times and ceiling effects. Test-retest reliability was assessed using weighted kappa and intraclass correlation coefficients (ICCs). Validity was tested with correlations between the EQ-5D-5L and WHOQoL-BREF and SF-12v2, and known-groups validity. Responsiveness was measured with standardized effect sizes (SES). RESULTS: The mean administration time was approximately 2 min, and the ceiling effect of the EQ-5D-5L index was 13.6 %. The weighted kappa values and ICC of the EQ-5D-5L were 0.48-0.61 and 0.82, respectively. Similar dimensions of the EQ-5D-5L had higher correlations with those of WHOQoL-BREF and SF-12v2. As expected, elderly, female, low-educated, unemployed, higher number of comorbidities and medicines, patients' perception of poor disease control, and having an adverse drug reaction tended to have poorer EQ-5D-5L scores. The SES of EQ-5D-5L index and EQ-VAS were considered small (0.33-0.42) for the improved group. For the worsened group, the SES of the EQ-5D-5L index were considered small (-0.29) but that of the EQ-VAS considered large (-0.82). CONCLUSIONS: The EQ-5D-5L was practical, reliable, valid, and responsive in Thai patients with chronic diseases.
PURPOSE: Due to the problem of high ceiling effects of the EQ-5D-3L, the EQ-5D-5L was developed. However, little was known about the full psychometric properties of the EQ-5D-5L. Thus, this study aimed to evaluate its practicality, reliability, validity, and responsiveness in Thai patients with chronic diseases. METHODS: One thousand one hundred and fifty-six adults taking a medicine at least 3 months were identified from three university hospitals in Bangkok, Thailand, between July 2014 and March 2015. Practicality was evaluated by administration times and ceiling effects. Test-retest reliability was assessed using weighted kappa and intraclass correlation coefficients (ICCs). Validity was tested with correlations between the EQ-5D-5L and WHOQoL-BREF and SF-12v2, and known-groups validity. Responsiveness was measured with standardized effect sizes (SES). RESULTS: The mean administration time was approximately 2 min, and the ceiling effect of the EQ-5D-5L index was 13.6 %. The weighted kappa values and ICC of the EQ-5D-5L were 0.48-0.61 and 0.82, respectively. Similar dimensions of the EQ-5D-5L had higher correlations with those of WHOQoL-BREF and SF-12v2. As expected, elderly, female, low-educated, unemployed, higher number of comorbidities and medicines, patients' perception of poor disease control, and having an adverse drug reaction tended to have poorer EQ-5D-5L scores. The SES of EQ-5D-5L index and EQ-VAS were considered small (0.33-0.42) for the improved group. For the worsened group, the SES of the EQ-5D-5L index were considered small (-0.29) but that of the EQ-VAS considered large (-0.82). CONCLUSIONS: The EQ-5D-5L was practical, reliable, valid, and responsive in Thai patients with chronic diseases.
Authors: Miguel Ángel García-Gordillo; Borja del Pozo-Cruz; José Carmelo Adsuar; Fernando Ignacio Sánchez-Martínez; José María Abellán-Perpiñán Journal: Qual Life Res Date: 2013-11-22 Impact factor: 4.147
Authors: Dominik Golicki; Maciej Niewada; Julia Buczek; Anna Karlińska; Adam Kobayashi; M F Janssen; A Simon Pickard Journal: Qual Life Res Date: 2014-10-28 Impact factor: 4.147
Authors: Krittaphas Kangwanrattanakul; Cynthia R Gross; Montaya Sunantiwat; Montarat Thavorncharoensap Journal: Qual Life Res Date: 2018-12-05 Impact factor: 4.147
Authors: Susanne Schmitz; Tatjana T Makovski; Roisin Adams; Marjan van den Akker; Saverio Stranges; Maurice P Zeegers Journal: Pharmacoeconomics Date: 2020-01 Impact factor: 4.981
Authors: Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147
Authors: Amaia Bilbao; Lidia García-Pérez; Juan Carlos Arenaza; Isidoro García; Gloria Ariza-Cardiel; Elisa Trujillo-Martín; Maria João Forjaz; Jesús Martín-Fernández Journal: Qual Life Res Date: 2018-07-05 Impact factor: 4.147
Authors: Akila R Jayamaha; Nimesha D M Herath; Nishadi D Dharmarathna; Hasini S Sandakumari; Nadeeka D K Ranadeva; Medhavi M Fernando; Nirmani A W Samarakoon; Priyangi N Amarabandu; Bhadrani Senanayake; Thamara Darshana; Nilani Renuka; Kerstin L Samarasinghe; Neluka Fernando Journal: Qual Life Res Date: 2022-10-16 Impact factor: 3.440
Authors: Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi Journal: Qual Life Res Date: 2020-09-15 Impact factor: 4.147